PROSOM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROSOM (PROSOM).
GABAA receptor agonist, potentiates GABAergic inhibition
| Metabolism | Hepatic via CYP3A4 and glucuronidation |
| Excretion | Renal: 80% as metabolites, primarily conjugated; unchanged drug <1%. Fecal: 15%. Biliary: minor. |
| Half-life | Terminal elimination half-life is approximately 20–30 hours (mean 25 h) in adults. Clinically, this supports once-daily dosing with potential for accumulation with repeated administration. |
| Protein binding | 95% bound, primarily to albumin. |
| Volume of Distribution | 0.5–1.0 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Oral: 80–95% due to minimal first-pass metabolism. No other relevant routes. |
| Onset of Action | Oral: 30–60 minutes for sedation; sleep induction within 15–45 minutes. No parenteral route approved. |
| Duration of Action | 6–8 hours for hypnotic effect; residual sedation may persist for 10–12 hours, particularly in elderly or hepatic impairment. |
0.5 mg orally once daily at bedtime for insomnia; maximum dose 1 mg.
| Dosage form | TABLET |
| Renal impairment | No specific adjustment recommended; use with caution in severe renal impairment. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 0.25 mg; Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | Initiate at 0.25 mg orally once daily at bedtime; increase cautiously if needed to 0.5 mg. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROSOM (PROSOM).
| Breastfeeding | Estazolam is excreted in breast milk. M/P ratio not established. Potential for infant sedation, poor feeding, and withdrawal. Breastfeeding is not recommended due to long half-life and risk of accumulation. |
| Teratogenic Risk | Pregnancy Category X. Estazolam is contraindicated in pregnancy due to benzodiazepine class effects. First trimester: increased risk of congenital malformations (cleft lip/palate, cardiac defects). Second/third trimesters: risk of fetal benzodiazepine syndrome, including hypotonia, respiratory depression, withdrawal symptoms. Neonatal effects: floppy infant syndrome, sedation, withdrawal seizures. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to quazepam or other benzodiazepines","Severe hepatic impairment","Narrow-angle glaucoma","Pregnancy","Breastfeeding"]
| Precautions | ["Risk of dependence and withdrawal","CNS depression","Respiratory depression","Anterograde amnesia","Complex sleep-related behaviors"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal sedation, respiratory rate, and signs of dependence. Fetal monitoring: assess fetal growth and development via ultrasound, monitor for neonatal withdrawal after delivery. No specific routine monitoring required beyond standard prenatal care if accidental exposure occurs. |
| Fertility Effects | No specific data on estazolam effects on fertility. Benzodiazepines may alter menstrual cyclicity or spermatogenesis at high doses based on animal studies. Clinically relevant effects are unlikely at therapeutic doses. |